Trials / Completed
CompletedNCT01348321
Comparison of Efficacy of Azithromycin and Levamisole Versus of Azithromycin in in the Treatment of Acne
Superior Efficacy of Azithromycin and Levamisole Versus of Azithromycin Alone in the Treatment of Inflammatory Acne Vulgaris: An Investigator Blind Randomized Clinical Trial on 169 Patients
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 169 (actual)
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
Different immunologic mechanisms contribute to development of inflammation in acne vulgaris and immunologic effect of levamisole has been demonstrated. Objective: The aim of this study was to compare azithromycin and levamisole with azithromycin alone in the treatment of acne vulgaris.
Detailed description
An investigator blind clinical randomized prospective two months study was designed. One hundred sixty nine acne patients presenting in our outpatients clinic were randomly allocated to two treatment groups: azithromycin and levamisole ( group 1 ) and azithromycin alone ( group 2 ) .One hundred forty eight patients completed the duration of the study and their clinical responses were evaluated and compared by using monthly photographic records .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levamisole | Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit. |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2011-05-05
- Last updated
- 2011-05-05
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT01348321. Inclusion in this directory is not an endorsement.